Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Pharmacokinetics · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| PF-00868554 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| Pharmacokinetics | DRUG | Single dose of 750 mg PF-00868554 as a solution and tablets. |
Inclusion Criteria: * Healthy volunteers. Exclusion Criteria: * Standard for healthy volunteers.
Pharmacokinetics is an investigational small molecule being studied for the treatment of Hepatitis C Virus. It is currently in Phase 1 clinical development and is not approved for any use. The drug is being developed by Pfizer, Inc. for the infectious disease indication.
Pharmacokinetics is being developed by Pfizer, Inc., a biopharmaceutical company traded on the New York Stock Exchange under the ticker symbol PFE. The drug is an investigational small molecule in Phase 1 clinical development for the treatment of Hepatitis C Virus.
Pharmacokinetics is in Phase 1 clinical development. It is an investigational drug and has not been approved by regulatory authorities. The drug is being studied for the treatment of Hepatitis C Virus, with one completed Phase 1 trial involving 14 participants.
Pharmacokinetics has one completed clinical trial registered under NCT00861458, titled "Bioavailability Study Of PF-00868554 Administered As 3x250mg Oral Tablets (Wet Granulate, 3x250mg Oral Tablets (Dry Granulate) And 750mg Solution Under Fed State." This Phase 1 study enrolled 14 healthy volunteers in Belgium.
Pharmacokinetics is also known as PF-00868554, as indicated by the clinical trial NCT00861458 which studies the drug under that name. The trial evaluates the bioavailability of PF-00868554 in different oral formulations for the treatment of Hepatitis C Virus.